IRE1 silencing downregulates cell cycle genes and engages TP53 and specific CDK inhibitors. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

Identification and validation of <i>Ctsz</i> as the lead candidate gene underlying <i>Tip5.</i> by Rachel K. Meade (22216529)

Subjects:

<i>IRF1</i> impacts VACV replication in glucose/IFN-γ primed but not galactose conditions. by Tyron Chang (9922533)

Significant cholesterol genes arranged by day. by Katherine M. Peterson (19746455)

“…Tiles represent the genes for each sample day when the P-value is ≤ 0.05. Genes with increased expression are blue; genes with decreased expression are orange; the depth of color reflects the magnitude of the increase or decrease. …”

IRE1 silencing downregulates cell cycle genes and engages TP53 and specific CDK inhibitors. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

Effect of down-regulation and up-regulation of CRNN on cell proliferation. by Changji Li (4806930)

Subjects:

Effect of down-regulation and up-regulation of CRNN on cell apoptosis. by Changji Li (4806930)

Subjects:

The effect of CRNN downregulation on migration and invasion ability in cSCC cells. by Changji Li (4806930)

Subjects:

CRNN over-expression promotes the growth of cSCC xenografts in vivo. by Changji Li (4806930)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects: